Pilot study of radiation therapy plus pembrolizumab for kidney cancer

A recent publication in the American Journal of Clinical Oncology this month reports on part of an exploratory study to look at the effect of radiotherapy alone or in combination with pembrolizumab on the immune system, and to determine the efficacy of this treatment in patients with solid tumours. This is the first study to look at the benefit of radiotherapy in combination with immune checkpoint inhibitors for the treatment of metastatic renal cell cancer (RCC).

The researchers concluded that the combination of radiotherapy with pembrolizumab in patients who had already been treated for metastatic RCC is well-tolerated and appears to have comparable efficacy with nivolumab when administered alone.

Read more in American Journal of Clinical Oncology here

Share this Post!

Related post